PSTV Plus Therapeutics: Bathi saben saham sajrone 12 wulan pungkasan

Plus Therapeutics, Inc. (PSTV) develops innovative radiopharmaceuticals using patented isotope nanodelivery for the targeted destruction of breast and brain tumors. The development process relies on a stable legal status in the US, as the business's humanitarian profile precludes geopolitical sanctions. The company's price chart reflects an EPS of 96.60, while investors should consider the risks of manufacturing complexity and R&D costs.
PSTV (Plus Therapeutics, Inc.): rincian analitis lan laporan miturut indikator

This indicator measures the dynamics of the rolling annual earnings per share, allowing for an assessment of net income generation efficiency relative to the previous period. Analyzing the EPS growth rate over the last 12 months YoY serves as a portfolio stress-testing tool, revealing the dependence of Plus Therapeutics, Inc. (PSTV) on constant secondary offerings and high development costs for radiopharmaceuticals.